Jordan Vaughn, MD
Internal Medicine · Birmingham, ALNPI 1639303506
Payments from drug & device makers
Across 183 payments — averaging $8982.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.6M
- Pfizer$399
- AstraZeneca$314
- Novo Nordisk$213
- Amgen$193
- Lilly USA, LLC$192
- plus $1K from 29 others
Across 5 payments — averaging $17,016 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$85K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 45 | $1,641,455 |
| Pfizer | 28 | $399 |
| AstraZeneca | 16 | $314 |
| Novo Nordisk | 13 | $213 |
| Amgen(2 entities) | 5 | $193 |
| Lilly USA, LLC | 12 | $192 |
| GSK | 12 | $183 |
| AbbVie(2 entities) | 10 | $159 |
| Boehringer Ingelheim | 4 | $60 |
| Johnson & Johnson | 3 | $57 |
| Dexcom, Inc. | 3 | $57 |
| Gilead | 3 | $45 |
| Seqirus USA Inc | 2 | $41 |
| Genentech USA, Inc. | 2 | $36 |
| Irhythm Technologies, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 1 | $28 |
| Shire North American Group Inc | 2 | $25 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Merck | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Inari Medical, Inc. | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Bayer | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Stryker | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $12 |
How this compares
$1,643,812 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Birmingham
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- William KirbyBirmingham$2.3M
- Stefanie KrickBirmingham$527K
- Ryan WeldonBirmingham$458K
- Ashraf KhanBirmingham$215K
- Robert LewisBirmingham$201K
- David WynneBirmingham$180K
- Kevin RiggsBirmingham$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.